Farms.com Home   Ag Industry News

Cattle Vaccination Could Avert 83% of Human E. Coli Cases, Study

Cattle Vaccination Could Avert 83% of Human E. Coli Cases, Study

By Amanda Brodhagen, Farms.com

A new study published in the Proceedings of the National Academy of Sciences suggests that using an E. coli vaccine on cattle could prevent about 83 percent of human infections.

The findings suggest that vaccination reduces the level of E. coli in bovine manure. There are currently two E. coli vaccinations available; a Canadian version – Econiche and the American version – Epitopix SRP.  To date, less than five-percent of the Canadian market is using the vaccine.

Researchers found that smaller cattle operations that raise, slaughter and sell their own cattle on farm are more likely to use the vaccine. These producers use the vaccine as a form of liability insurance. Advocates of the vaccine being used more broadly argue that vaccination is not only an agriculture issue, but a health one.
 


Trending Video

A new era in biostimulants and bionutritionals

Video: A new era in biostimulants and bionutritionals


In response to the growing need for efficient, effective biosolutions, HGS BioScience continues to expand its footprint in the bionutritional and biostimulant market with the acquisition of NutriAg, Ltd. The Paine Schwartz Partners-backed HGS BioScience is a global leader in humic and fulvic acid products. Toronto-based NutriAg is an innovator in bionutritional technologies with a deep R&D engine. North American growers and retailers will benefit from:

• Solutions across the biostimulant spectrum - including humics, fulvics, bionutritionals, carbohydrate chelation, amino acids, plant and seaweed extracts, and microbial technologies.
• A portfolio and R&D pipeline of science-backed solutions proven to drive crop productivity and farm profitability.
• Actionable nutrient insights and recommendations based on data specific to their farm and cropping goals with the NutriAnalytics platform